A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Abstract Text:

Deborah K Armstrong,Gini F Fleming,Maurie Markman,Howard H Bailey,

OBJECTIVES: Paclimer is a biodegradable polymer microsphere formulation containing 10% (w/w) paclitaxel that is designed to provide a sustained-release form of paclitaxel after intraperitoneal (IP) administration. The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration. METHODS: Twelve patients with recurrent or persistent ovarian or primary peritoneal carcinoma were treated. After placement of an IP catheter, patients were treated with escalating doses of IP paclitaxel microspheres administered with 2 l of normal saline following premedication. Treatment could be repeated once, 8 weeks after initial treatment. The starting dose was 60 mg/m2 and no intrapatient dose escalation was used. RESULTS: One dose-limiting toxicity consisting of abdominal pain, ileus and bowel obstruction was seen with the second cycle of therapy in one patient who received 900 mg/m2. Patients received up to 1200 mg/m2 without further evidence of dose-limiting toxicities (DLT). The study was discontinued before MTD was defined due to the manufacturer's decision to suspend further clinical development of paclitaxel microspheres. Pharmacokinetic analysis showed a trend toward a dose-dependent effect of IP paclitaxel microspheres on measured plasma paclitaxel levels. Sustained paclitaxel levels were maintained throughout all 8 weeks of therapy; however, paclitaxel concentrations were well below the plasma concentrations associated with toxicity. In one patient, laparoscopy revealed extensive adhesions, fat necrosis, foreign body giant cell reaction and detectable residual polymer filaments 7 months after completion of treatment with paclitaxel microspheres. CONCLUSIONS: IP administration of paclitaxel microspheres is well tolerated up to 1200 mg/m2 without defining MTD. The low but persistent detection of plasma paclitaxel indicates that paclitaxel continues to be released for at least 8 weeks after IP paclitaxel microsphere treatment. The finding of significant peritoneal abnormalities, including the presence of residual polymer filaments, months after IP Paclimer treatment suggests that the polymer preparation used in Paclimer degrades slowly.

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Publishing Authors By Initials

DK Armstrong,GF Fleming,M Markman,HH Bailey,

For similar organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids: paclitaxel research abstracts see: organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids: paclitaxel research

PUBMED ID PMID:

MEDLINE DATE:

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Gynecologic oncology

VOLUME: 103

Page Numbers: 391-6

Journal Abbreviation: Gynecol. Oncol.

ISSN: 0090-8258

DAY: 19

MONTH: 04

YEAR: 2006

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 365304

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Keywords Mesh Terms:

KEYWORDS: Paclitaxel

MESH TERMS: pharmacokinetics

Chemical & Substance for Abstract: A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Information

Substance Name: Paclitaxel

Registry Number: 33069-62-4

Grant and Affiliation Information for A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.

AFFILIATION: John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA. darmstro@welchlink.welch.jhu.edu

Country: United States

AGENCY: United States NCI

GRANT: CA 37517

ACRONYM: CA

MEDLINETA: Gynecol Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres Paclimer in recurrent ovarian cancer: a Gynecologic Oncology Group study Related Publications

• A Note on "Isolation and Pharmacological Action of Heliotrine, the Major Alkaloid of Heliotropium indicum Seeds".
• A festschrift for J. Martyn Bailey, a biochemist extraordinaire.
• A mechanistic analysis of stone fracture in lithotripsy.
• A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
• ADHD symptoms in children with FXS.
• Cooling augments vasoconstriction mediated by 5-HT1 and alpha2-adrenoceptors in the isolated equine digital vein: involvement of Rho kinase.
• DNA double-strand breaks are not sufficient to initiate recruitment of TRF2.
• Effects of ultrasonography on the bovine testis and semen quality.
• Exercise-induced brachial artery vasodilation: role of free radicals.
• Federal policy leading the way in emergency medical services.
• Higher-order suppression in diffraction-grating monochromators using thin films.
• Holo-transcobalamin is an indicator of vitamin B-12 absorption in healthy adults with adequate vitamin B-12 status.
• Implementation of virtual medical record object model for a standards-based clinical decision support rule engine.
• Intervention to improve dyslipidemia screening in hospitalized diabetics.
• Isolation of chlorophylls a and b from spinach by counter-current chromatography.
• Lack of Relationship between Functional and Perceived Quality of Life Outcomes following Pulmonary Rehabilitation: 1940: Board #10 May 31 2:00 PM - 3:30 PM.
• Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
• Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries.
• Natural chlorophyll inhibits aflatoxin B1-induced multi-organ carcinogenesis in the rat.
• Prospective validation of an algorithm to identify hospitalized diabetic patients using administrative data.
• Reply to ramamurthi and rahman: induction of ptosis with botulinum toxin for thr treatment of recurrent corneal erosions.
• Self-image, self-concept, and self-identity revisited.
• Serotonin-induced regulation of the actin network for learning-related synaptic growth requires Cdc42, N-WASP, and PAK in Aplysia sensory neurons.
• Sustained attention and response inhibition in boys with fragile X syndrome: measures of continuous performance.
• The Effects of an 8 week Mentoring Program on Body Image in Adolescent Girls: 2257: Board #170 June 1 8:00 AM - 9:30 AM.
• The foundation of self-esteem.
• The importance of carcinogen dose in chemoprevention studies: quantitative interrelationships between, dibenzo[a,l]pyrene dose, chlorophyllin dose, target organ DNA adduct biomarkers and final tumor outcome.
• Tissue endostatin correlates inversely with capillary network in rat heart and skeletal muscles.
• Trachoma and fly control.
• Using BPEL to define an executable CDS rule process.